Methylthioadenosine
(Synonyms: 5-脱氧-5-甲硫腺苷,5'-(Methylthio)-5'-deoxyadenosine; 5'-Deoxy-5'-(methylthio)adenosine; 5'-S-Methyl-5'-thioadenosine) 目录号 : GC11222
A natural derivative of SAM
Cas No.:2457-80-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Ki = 62 μM for S49-derived high-affinity cAMP phosphodiesterase
Methylthioadenosine (MTA) is a naturally occurring sulfur-containing nucleoside in all mammalian tissues. MTA is mainly produced from S-adenosylmethionine via the polyamine biosynthetic pathway, behaving as a powerful inhibitory product.
In vitro: MTA was found to be solely metabolized by MTA-phosphorylase, to yield 5-methylthioribose-1-phosphate and adenine, which was a key step in methionine and purine salvage pathways, respectively. Previous studies suggested that MTA coud affect various cellular processes. MTA had been shown to be albe to influence plenty of critical cell responses, such as proliferation, gene expression regulation, differentiation as well as apoptosis. Though most of such responses had been only observed at the pharmacological level, their specificity made it tempting to speculate that endogenous MTA might play a regulatory role in the cell [1].
In vivo: The hepatoprotective effects of MTA had been evaluated in a model of CCl4-induced chronic liver damage in rats. In this study, MTA could reproduce the human lesions induced by alcohol and viral infections of the liver. In addition, replenishment of the hepatic pool of MTA showed strong anti-oxidant effects and also reduced liver cell damage and fibrosis [2].
Clinical trial: Up to now, MTA is still in the preclinical development stage.
References:
[1] Avila MA,García-Trevijano ER,Lu SC,Corrales FJ,Mato JM. Methylthioadenosine. Int J Biochem Cell Biol.2004 Nov;36(11):2125-30.
[2] Pascale RM,Simile MM,De Miglio MR,Feo F. Chemoprevention of hepatocarcinogenesis: S-adenosyl-L-methionine. Alcohol.2002 Jul;27(3):193-8.
| Cas No. | 2457-80-9 | SDF | |
| 别名 | 5-脱氧-5-甲硫腺苷,5'-(Methylthio)-5'-deoxyadenosine; 5'-Deoxy-5'-(methylthio)adenosine; 5'-S-Methyl-5'-thioadenosine | ||
| 化学名 | (2R,3R,4S,5S)-2-(6-amino-9H-purin-9-yl)-5-((methylthio)methyl)tetrahydrofuran-3,4-diol | ||
| Canonical SMILES | CSC[C@](O1)([H])[C@](O)([H])[C@](O)([H])[C@]1([H])N2C=NC(C2=NC=N3)=C3N | ||
| 分子式 | C11H15N5O3S | 分子量 | 297.33 |
| 溶解度 | ≥ 83.3mg/mL in DMSO with gentle warming | 储存条件 | Store at -20°C,protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.3633 mL | 16.8163 mL | 33.6327 mL |
| 5 mM | 0.6727 mL | 3.3633 mL | 6.7265 mL |
| 10 mM | 0.3363 mL | 1.6816 mL | 3.3633 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >97.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet